New Connected Devices Seek to Tackle Drug Noncompliance

Noncompliance with drug regimens continues to be a significant healthcare concern. “Today, 60% of patients fail to comply with their medication regimen,” Sai Shankar, director business development - connected devices for Aptar Pharma, tells MD+DI.   Aptar Pharma believes that turning metered-dose inhalers (MDIs) and dry-powder inhalers (DPIs) into connected devices could have an impact. “This can improve patient engagement and significantly increase dose adherence and improve patient health outcomes, as patients manage their treatments more effectively,” says Shankar. “Connected devices provide objective monitoring and real-time data with digital solutions. This improves patient adherence, which reduces hospitalization events in chronic diseases. Hospitalization reduction decreases costs to payers, creating value in healthcare system.”   Aptar Pharma is partnering with a digital health solution provider to develop a portfolio of connected devices such as MDIs and DPIs. “Aptar Pharma offers drug-delivery devices that can bring in the full connected functionality and integrate them with software solutions that are accessible to patients/consumers,” he says.   The company will be highlighting several technologies at the upcoming CPhI Worldwide on October 24-26, 2017, at Messe Frankfurt, Germany.   “For respiratory, we will be featuring our c-Devices portfolio at CPhI, which includes our connected pMDI, connected BAI Platform, and Connected ...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news